Meningeal contrast enhancement in multiple sclerosis: Assessment of field strength, acquisition delay, and clinical relevance
- PMID: 38809920
- PMCID: PMC11135724
- DOI: 10.1371/journal.pone.0300298
Meningeal contrast enhancement in multiple sclerosis: Assessment of field strength, acquisition delay, and clinical relevance
Abstract
Background/purpose: Leptomeningeal enhancement (LME) on post-contrast FLAIR is described as a potential biomarker of meningeal inflammation in multiple sclerosis (MS). Here we report an assessment of the impact of MRI field strength and acquisition timing on meningeal contrast enhancement (MCE).
Methods: This was a cross-sectional, observational study of 95 participants with MS and 17 healthy controls (HC) subjects. Each participant underwent an MRI of the brain on both a 7 Tesla (7T) and 3 Tesla (3T) MRI scanner. 7T protocols included a FLAIR image before, soon after (Gd+ Early 7T FLAIR), and 23 minutes after gadolinium (Gd+ Delayed 7T FLAIR). 3T protocol included FLAIR before and 21 minutes after gadolinium (Gd+ Delayed 3T FLAIR).
Results: LME was seen in 23.3% of participants with MS on Gd+ Delayed 3T FLAIR, 47.4% on Gd+ Early 7T FLAIR (p = 0.002) and 57.9% on Gd+ Delayed 7T FLAIR (p < 0.001 and p = 0.008, respectively). The count and volume of LME, leptomeningeal and paravascular enhancement (LMPE), and paravascular and dural enhancement (PDE) were all highest for Gd+ Delayed 7T FLAIR and lowest for Gd+ Delayed 3T FLAIR. Non-significant trends were seen for higher proportion, counts, and volumes for LME and PDE in MS compared to HCs. The rate of LMPE was different between MS and HCs on Gd+ Delayed 7T FLAIR (98.9% vs 82.4%, p = 0.003). MS participants with LME on Gd+ Delayed 7T FLAIR were older (47.6 (10.6) years) than those without (42.0 (9.7), p = 0.008).
Conclusion: 7T MRI and a delay after contrast injection increased sensitivity for all forms of MCE. However, the lack of difference between groups for LME and its association with age calls into question its relevance as a biomarker of meningeal inflammation in MS.
Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Conflict of interest statement
Dr. Harrison has received research funding from EMD-Serono and Roche-Genentech and royalties/consulting fees from the American College of Physicians, Horizon Therapeutics, TG Therapeutics, EMD-Serono, and UpToDate Inc. Drs. Allette, Zeng, Cohen, Dahal, Choi, Zhuo and Hua are without disclosures. These relationships do not alter our adherence to PLOS ONE policies on sharing data and materials.
Figures
Update of
-
Meningeal contrast enhancement in multiple sclerosis: assessment of field strength, acquisition delay, and clinical relevance.medRxiv [Preprint]. 2024 Mar 7:2024.03.04.24303491. doi: 10.1101/2024.03.04.24303491. medRxiv. 2024. Update in: PLoS One. 2024 May 29;19(5):e0300298. doi: 10.1371/journal.pone.0300298. PMID: 38496664 Free PMC article. Updated. Preprint.
References
-
- Vercellino M, Costantini G, Cogoni M, Lequio L, Sciortino P, De Negri F, et al.. Association of MRI leptomeningeal enhancement with disability worsening in progressive multiple sclerosis: A clinical and post-mortem study. Mult Scler. 2023:13524585231199031. Epub 2023/09/23 20:41. doi: 10.1177/13524585231199031 . - DOI - PubMed
-
- Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al.. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130(Pt 4):1089–104. Epub 2007/04/18. doi: 10.1093/brain/awm038 . - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
